Interneuron Redux Settlement Offer Denied Due To Valuation "Uncertainty"

The unpredictability of Interneuron's future cash-flow served as a basis of Eastern District of Pennsylvania Judge Louis Bechtle's Sept. 27 decision to deny the company's proposed settlement for diet drug Redux medical claims.